康基医疗2025中期报告

2025INTERIM REPORT中期報告 Contents 2Corporate Information4Financial Highlights5Management Discussion and Analysis24Corporate Governance and Other Information37Interim Condensed Consolidated Statement of Profit or Loss and OtherComprehensive Income39Interim Condensed Consolidated Statement of Financial Position41Interim Condensed Consolidated Statement of Changes in Equity43Interim Condensed Consolidated Statement of Cash Flows46Notes to the Interim Condensed Consolidated Financial Information70Definitions Corporate Information BOARD OF DIRECTORSExecutive DirectorsMr. ZHONG Ming(Chairman)Ms. SHENTU YinguangMr. YIN Zixin Non-executive DirectorMs. CAI Li Independent Non-executive DirectorsMr. JIANG FengMr. GUO JianMr. CHEN Weibo AUDIT COMMITTEEMr. CHEN Weibo(Chairman)Mr. JIANG FengMs. CAI Li REMUNERATION COMMITTEEMr. CHEN Weibo(Chairman)Ms. SHENTU YinguangMr. GUO Jian 20255232025523 NOMINATION COMMITTEE Mr. JIANG Feng(Chairman)Ms. SHENTU Yinguang(with effect from May 23, 2025)Mr. GUO JianMr. ZHONG Ming(ceased on May 23, 2025) ENVIRONMENTAL, SOCIAL AND GOVERNANCECOMMITTEE Mr. ZHONG Ming(Chairman)Ms. SHENTU YinguangMr. YIN Zixin COMPANY SECRETARYMr. WAN Siu Keung AUTHORIZED REPRESENTATIVESMr. ZHONG MingMr. YIN Zixin 97927 AUDITOR Ernst & YoungCertified Public AccountantsRegistered Public Interest Entity Auditor27/F, One Taikoo Place979 King’s RoadQuarry BayHong Kong Corporate Information REGISTERED OFFICE Appleby Global Services (Cayman) Limited71 Fort StreetP.O. Box 500George TownGrand Cayman KY1-1106Cayman Islands Appleby Global Services (Cayman) Limited71 Fort StreetP.O. Box 500George TownGrand Cayman KY1-1106Cayman Islands CORPORATE HEADQUARTERS 1668 No. 1668 Chunjiang East RoadTonglu Economic Development ZoneHangzhouZhejiang ProvincePRC 50037 HONG KONG LEGAL ADVISER Cleary Gottlieb Steen & Hamilton (Hong Kong)37/F, Hysan Place500 Hennessy RoadCauseway BayHong Kong 100101007B PRINCIPAL PLACE OF BUSINESS IN HONG KONG Flat 1007B, 10/F, Harbour Crystal Centre100 Granville Road, KowloonHong Kong HONG KONG SHARE REGISTRAR 183171712–1716 Computershare Hong Kong Investor Services LimitedShops 1712–1716, 17th FloorHopewell Centre183 Queen’s Road EastWanchaiHong Kong +86 571 69900020ir@kangji.com INVESTOR RELATIONST: +86 571 69900020E: ir@kangji.com www.kangjimedical.com WEBSITEwww.kangjimedical.com 9997 STOCK CODE9997 Financial Highlights The financial highlights of the Group for the Reporting Period togetherwith the comparative figures for the corresponding period in the fourfinancial periods, as extracted from/calculated based on the unauditedfinancial information and financial statements are set out as follows: 496.620248.3% For the Reporting Period, the Company realized revenue of RMB496.6m i l l i o n , r e p r e s e n t i n g a n i n c r e a s e o f 8 . 3 % a s c o m p a r e d t o t h ecorresponding period in 2024. The Group’s increase in sales was mainlyattributable to the increase in sales of disposable products. 2024285.87.0%2025265.8 The Group’s net profit attributable to owners of the parent for theReporting Period decreased by 7.0% from RMB285.8 million in 2024 toRMB265.8 million in 2025. The decrease was mainly due to the decreasein other income and gains and the increase in the Group’s share of lossin Weijing Medical. 20256 30 The Board did not recommend the payment of any interim dividend forthe six months ended June 30, 2025. Management Discussion and Analysis BUSINESS OVERVIEW AND OUTLOOK 202563040.46% The Group is a leading China-based medical device platform specializingin minimally invasive surgery, with a mission to empower physiciansand improve health and wellness of patients through providing highperforming, reliable and accessible products and services. As of June30, 2025, the Group holds approximately 40.46% equity interest inWeijing Medical, a Chinese company focused on the research anddevelopment, manufacturing and sale of laparoscopic surgical robots. 20252025 In the first half of 2025, China’s medical device industry continued toundergo a critical period of structural adjustment. In terms of macroindustry policies, China persistently deepened healthcare reforms,and the coverage of the VBP policy was further expanded, exertingpressure on the prices of related products. Meanwhile, industry-wideanti-corruption initiative continued, posing challenges to the growthof both existing and new products. In terms of competition, industryintegration persisted. However, there were still many market playersand the competition was intense, which placed higher demands oncompanies with strong brand advantages. To address these challenges,the Group proactively accelerated innovation, launched new products,and implemented various measures to reduce costs and enhanceefficiency. Looking back at the first half of 2025, through its dual-growth strategy focusing on both domestic and overseas markets, theGroup’s revenue achieved steady growth. During the Reporti